Third, more cases with atypical/inconclusive genetic findings or belong to rare subtypes should also be included in the validation cohort, such as CLL carrying the IGH-BCL2 translocation, FL without the IGH-BCL2 translocation, Cyclin D1-negative cMCL, or SBCLN, not otherwise specified (NOS) cases. This evidence concerns the gene CCND1 and B-cell chronic lymphocytic leukemia.